AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial Reuters
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Reuters
In short
AstraZeneca and Amgen's asthma drug achieved a 69% remission rate in treating esophageal disease, potentially revolutionizing treatment options for esophageal disorders. This breakthrough could lead to better quality of life for patients.
Key points
- AstraZeneca and Amgen's asthma medication showed a 69% remission rate in esophageal disea…: AstraZeneca and Amgen's asthma medication showed a 69% remission rate in esophageal disease.
- This development could lead to new treatment options for esophageal disorders.: This development could lead to new treatment options for esophageal disorders.
- It offers hope for patients suffering from esophageal diseases, potentially improving the…: It offers hope for patients suffering from esophageal diseases, potentially improving their quality of life.